Goal is to Enhance Patient Safety and Reduce Health Care Costs
This pilot hemovigilance program is one of four components comprising the U.S. Biovigilance Network. The U.S. Biovigilance Network is the first and only national collaboration between government and nongovernment agencies designed to confidentially track adverse reactions and incidents associated with blood collection and transfusion as well as tissue, organ and cell therapy transplantation. The Hemovigilance Module - focusing specifically on patients who receive blood and blood components -- is being developed within the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network (NHSN), a patient safety surveillance system operated by the CDC's Division of Healthcare Quality Promotion.
"The U.S. is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level," said AABB CEO
Though the U.S. blood supply is as safe as it has ever been, this country lacks a coordinated national network to track and monitor adverse events associated with the transfusion of blood and blood components. Fully reliable data about the relative risks of transfusion do not exist, particularly concerning life-threatening noninfectious hazards of transfusion such as transfusion of the wrong unit of blood into a patient and transfusion-related acute lung injury, or TRALI.
TRALI is just one of many examples of how mitigating the current adverse events associated with transfusions would produce large health care savings nationally and, most importantly, enhance patient safety. For patients at risk for TRALI, data collected and compiled from the Hemovigilance Module could lead to the development of new treatment protocols. In addition to improved care, an estimated
"The Hemovigilance Module in NHSN is an important step forward for blood safety in
Established in 1947, AABB (formerly known as the American Association of Blood Banks) is an international, not-for-profit association dedicated to the advancement of science and the practice of transfusion medicine and related biological therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs and services to optimize patient and donor care and safety. AABB membership consists of approximately 1,800 institutions and 8,000 individuals, including physicians, scientists, administrators, medical technologists, nurses, researchers, blood donor recruiters and public relations personnel. Members are located in all 50 states and 80 countries.